Evidence map›Paper›PMID 36810524›Full record

ReviewSignal transduction and targeted therapy2023

Signaling pathways in Parkinson's disease: molecular mechanisms and therapeutic interventions.

Xu Dong-Chen, Chen Yong, Xu Yang, ShenTu Chen-Yu, Peng Li-Hua

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Signal transduction and targeted therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 234 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
234citing papers in PubMed, 6 pooled it
56.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

234 citing papers in PubMed, 6 syntheses or guidelines pooled it, 377 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Synthetic Cyclic CAntioxidants (Basel, Switzerland) · 2026
    Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Review

174 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Xu Dong-Chen *College of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, P. R. China.
Chen Yong *College of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, P. R. China.
Xu YangCollege of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, P. R. China.
ShenTu Chen-YuCollege of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, P. R. China.
Peng Li-HuaCollege of Pharmaceutical Sciences, Zhejiang University, 310058, Hangzhou, P. R. China. lhpeng@zju.edu.cn.ORCID 0000-0001-9763-383X
Zhejiang University · CNMacau University of Science and Technology · MO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Parkinson's disease (PD) is the second most common neurodegenerative disease worldwide, and its treatment remains a big challenge. The pathogenesis of PD may be related to environmental and genetic factors, and exposure to toxins and gene mutations may be the beginning of brain lesions. The identified mechanisms of PD include α-synuclein aggregation, oxidative stress, ferroptosis, mitochondrial dysfunction, neuroinflammation, and gut dysbiosis. The interactions among these molecular mechanisms complicate the pathogenesis of PD and pose great challenges to drug development. At the same time, the diagnosis and detection of PD are also one of obstacles to the treatment of PD due to its long latency and complex mechanism. Most conventional therapeutic interventions for PD possess limited effects and have serious side effects, heightening the need to develop novel treatments for this disease. In this review, we systematically summarized the pathogenesis, especially the molecular mechanisms of PD, the classical research models, clinical diagnostic criteria, and the reported drug therapy strategies, as well as the newly reported drug candidates in clinical trials. We also shed light on the components derived from medicinal plants that are newly identified for their effects in PD treatment, with the expectation to provide the summary and outlook for developing the next generation of drugs and preparations for PD therapy.

Indexed as

Neurodegenerative DiseasesParkinson DiseaseHumansMutationOxidative StressSignal Transduction

Identifiers

PMID36810524
PMCPMC9944326
OpenAlexW4321452638

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.